Medical marijuana is now a legal treatment for post-traumatic stress disorder (PTSD) in Colorado. Governor John Hickenlooper signed SB17-017 on June 5, 2017, officially giving doctors the green light to prescribe cannabis to patients suffering with post-traumatic stress disorder (PTSD). Colorado joins at least 20 other states in allowing cannabis-based treatments for the disorder. [1]
Yet another study shows the natural healing power of marijuana, and it could give hope to the millions of people who suffer from chronic migraines.
President Donald Trump’s stance on legalizing medical cannabis is a big question mark, and Attorney General Jeff Sessions hates marijuana and has expressed his intent to stiffen drug penalties. But there is at least one person in the government who sees the potential of marijuana as a medicine, and that person is Veterans Affairs (VA) Secretary David Shulkin.
Marijuana has been associated with reducing seizures in people with epilepsy for years, but only now is the topic getting more of the scientific scrutiny it deserves. In a recent study, cannabidiol (CBD) reduced the number of seizures by half in a substantial number of children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy.
GW Pharmaceuticals, a developer of cannabidiol, sponsored the study.
The findings of a Yahoo News/Marist poll show that people over the age of 69 generally don’t have positive views of marijuana. While the majority of younger Americans increasingly view marijuana as a legitimate medication and relatively acceptable recreational substance, the older crowd has been slower to adopt these views.
(ANTIMEDIA) In first-of-their-kind actions, legislatures in two states, Vermont and New Hampshire, moved to decriminalize adult marijuana use this week. From a press release on Vermont by the National Organization for the Reform of Marijuana Laws (NORML):
(ANTIMEDIA) One-third of FDA-approved drugs were later found to have safety risks, according to a recent analysis of drugs cleared by the agency between 2001 and 2010.
According to the study, published in the Journal of the American Medical Association, “Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 71 (32.0%) were affected by a postmarket safety event.”
